Avalo Therapeutics (NASDAQ:AVTX) Earns Buy Rating from Analysts at Jefferies Financial Group

Jefferies Financial Group assumed coverage on shares of Avalo Therapeutics (NASDAQ:AVTX) in a research note released on Tuesday, MarketBeat reports. The brokerage issued a buy rating and a $23.00 price objective on the stock.

AVTX has been the topic of a number of other reports. BTIG Research started coverage on shares of Avalo Therapeutics in a report on Thursday, December 19th. They set a “buy” rating and a $40.00 price objective on the stock. Stifel Nicolaus assumed coverage on shares of Avalo Therapeutics in a report on Tuesday. They set a “buy” rating and a $36.00 price target on the stock. Wedbush reiterated an “outperform” rating and issued a $18.00 price objective on shares of Avalo Therapeutics in a research note on Thursday, March 20th. Piper Sandler assumed coverage on shares of Avalo Therapeutics in a research report on Friday, February 28th. They set an “overweight” rating and a $48.00 target price on the stock. Finally, HC Wainwright reaffirmed a “neutral” rating on shares of Avalo Therapeutics in a research report on Thursday, March 20th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, Avalo Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $33.00.

Avalo Therapeutics Price Performance

NASDAQ:AVTX opened at $8.73 on Tuesday. The company has a 50 day simple moving average of $7.59 and a two-hundred day simple moving average of $9.13. Avalo Therapeutics has a fifty-two week low of $5.99 and a fifty-two week high of $34.46.

Hedge Funds Weigh In On Avalo Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of AVTX. Tower Research Capital LLC TRC raised its stake in Avalo Therapeutics by 998.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company’s stock valued at $31,000 after acquiring an additional 3,754 shares during the period. Marshall Wace LLP purchased a new stake in shares of Avalo Therapeutics during the fourth quarter worth $114,000. Walleye Capital LLC purchased a new position in shares of Avalo Therapeutics in the fourth quarter valued at $145,000. Northern Trust Corp bought a new stake in shares of Avalo Therapeutics during the 4th quarter valued at $168,000. Finally, Bank of Montreal Can bought a new stake in shares of Avalo Therapeutics during the fourth quarter valued at about $446,000. 87.06% of the stock is owned by institutional investors.

About Avalo Therapeutics

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.